NCT06062420 2026-01-09A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202GlaxoSmithKlinePhase 2 Active not recruiting316 enrolled
NCT05277051 2025-12-19First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsGlaxoSmithKlinePhase 1 Recruiting158 enrolled